Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study

• Paolo Strati,
• Sven de Vos,
• Jia Ruan,
• Kami J. Maddocks,
• Christopher R. Flowers,
• Simon Rule,
• Priti Patel,
• Yan Xu,
• Helen Wei,
• Melanie M. Frigault,
• Roser Calvo,
• Martin J.S. Dyer

Affiliations

Paolo Strati

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX

Sven de Vos

Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA

Jia Ruan

Division of Hematology and Medical Oncology,Meyer Cancer Center, Weill Cornell Medicine, New York, NY

Kami J. Maddocks

Division of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH

Christopher R. Flowers

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Winship Cancer Institute of Emory University, Atlanta, GA

Simon Rule

Department of Haematology, Plymouth University Medical School, Plymouth

Priti Patel

AstraZeneca, South San Francisco, CA

Yan Xu

AstraZeneca, South San Francisco, CA

Helen Wei

AstraZeneca, South San Francisco, CA

Melanie M. Frigault

AstraZeneca, South San Francisco, CA

Roser Calvo

AstraZeneca, Gaithersburg, MD

Martin J.S. Dyer

Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester